Pay in 4 interest-free payments of $5.75 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Southern Weight Loss provides specialist obesity care across Otago and Southland with integrated medical and surgical pathways
Jiangsu Hengrui Pharmaceuticals licenses portfolio of GLP-1-based drug candidates Deal announced: 17 May 2024 Potential deal value: $6,035 million Deal overview: Jiangsu Hengrui Pharmaceuticals, a company headquartered in Lianyungang, China, licensed three GLP-1-based investigational drug candidates to a newly founded company originally known as Hercules CM NewCo, backed by investors including Atlas Venture, Bain Capital and RTW
Imadojemu et al
FDA Regulations FDA compounding compliance under Sections 503A and 503B is a cornerstone of what we do for GLP-1 clients
.webp)
US$ 20.89
US$ 20.45
US$ 26.64
US$ 22.25
US$ 27.59
